Vidac Pharma Holding PLC: management transactions · Germany · BaFin

About Vidac Pharma Holding PLC

Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company listed on Xetra / Frankfurt (DAX/MDAX/SDAX) in Germany, with a clear focus on oncology and onco-dermatology. Founded in 2012, the company is developing first-in-class therapies built around a scientific approach to cancer metabolism, aiming to address abnormal metabolic processes observed in cancer cells. That positioning gives Vidac a differentiated profile versus many micro-cap healthcare names that rely mainly on reformulations or late-stage licensing plays. ([vidacpharma.com](https://vidacpharma.com/en/about-us/about-us?utm_source=openai)) Although the company’s registered address is in London at 20-22 Wenlock Road, London N1 7GU, United Kingdom, its equity-market visibility for continental investors is centered on Germany through Xetra and also Tradegate. For investors in France, Belgium and Switzerland, that means the stock is effectively accessed through the German market infrastructure, even if the operating footprint is international. ([vidacpharma.com](https://vidacpharma.com/en/about-us/about-us?utm_source=openai)) Vidac’s business model is focused on two main therapeutic areas: oncology and onco-dermatology. Its lead program, VDA-1102, is being developed for indications including actinic keratosis and cutaneous T-cell lymphoma (CTCL). The company also highlights VDA-1275, a next-generation candidate in preclinical development with broader potential in solid tumors. In other words, the investment case is still largely pipeline-driven, with limited diversification but a clearly articulated scientific thesis. ([vidacpharma.com](https://vidacpharma.com/en/about-us/about-us?utm_source=openai)) From a competitive standpoint, Vidac operates in a highly contested biotech environment where differentiation depends on the strength of the biology, patent protection, and the quality of clinical translation. The company frames its platform around the Warburg effect and a mechanism intended to restore more normal cellular regulation. That gives it a distinct technological narrative, but it also means the stock remains exposed to the typical risks of clinical-stage biotech: trial outcomes, regulatory uncertainty, and financing needs. ([vidacpharma.com](https://vidacpharma.com/en/about-us/about-us?utm_source=openai)) Recent company updates point to continued scientific execution. In 2026, Vidac announced a study to be conducted by PharmaLegacy and reported receipt of a Notice of Allowance from the USPTO for a new patent covering a synthesis pathway for VDA-1102. The company has also disclosed manager transactions under MAR Article 19, which is relevant for German-market investors monitoring insider activity and governance transparency. These developments suggest a business still in the value-creation phase, with catalysts tied to patent progress, clinical development and capital markets access. ([vidacpharma.com](https://vidacpharma.com/en/press-releases?utm_source=openai))